Phase 1/1b Study of the Efficacy and Safety of the Combination of Panobinostat Plus Carfilzomib in Patients With Relapsed/Refractory Myeloma

Trial Profile

Phase 1/1b Study of the Efficacy and Safety of the Combination of Panobinostat Plus Carfilzomib in Patients With Relapsed/Refractory Myeloma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 29 May 2018

At a glance

  • Drugs Carfilzomib (Primary) ; Panobinostat (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Most Recent Events

    • 02 Mar 2018 Planned End Date changed from 1 Aug 2019 to 1 Aug 2020.
    • 17 Jan 2018 Planned End Date changed from 1 Aug 2018 to 1 Aug 2019.
    • 17 Jan 2018 Planned primary completion date changed from 1 Aug 2018 to 1 Aug 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top